B. C. Trauth

TL;DR: Histological thin sections of the regressing tumor showed that anti-APO-1 was able to induce apoptosis in vivo, suggesting induction of apoptosis as a consequence of a signal mediated through cell surface molecules like APO- 1 may be a useful therapeutic approach in treatment of malignancy.

TL;DR: The APO-1 antigen was expressed upon transfection of APo-1 cDNA into BL60-P7 Burkitt's lymphoma cells and conferred sensitivity towards anti-APO- 1-induced apoptosis to the transfectants.

TL;DR: The data show that selective targeting of apoptosis to tumors may be an efficient antitumor mechanism and suggests that cross-linking of APO-1 on the tumor cell surface may also be required for tumor regression by apoptosis in vivo.

TL;DR: The sensitivity of lymphoblastoid cell lines to anti-APO-1-mediated apoptosis may open a new therapeutic approach for the treatment of EBV- induced lymphoproliferative lesions in immunocompromised individuals, because these are composed of cells with a lymphobstonoid phenotype.

TL;DR: This research attacked the mode of action of E.P.C.H.’s “cell reprograming” by focusing on the “spatially-based” component of the immune response to cancer.